In-vitro susceptibility of Streptococcus pneumoniae to the d- and I-isomers of ofloxacin: Interpretive criteria and quality control limits

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue 2, 1996, Pages 365-369

  Barry, A L ^a   Fuchs, P C ^a,b   Allen, S D ^c   Brown, S D ^a   Jorgensen, J H ^d   Tenover, F C ^e  

^a CLINICAL MICROBIOLOGY INSTITUTE   (United States)

^b PROVIDENCE ST VINCENT MEDICAL CENTER   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; QUALITY CONTROL; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; DATA INTERPRETATION, STATISTICAL; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; STEREOISOMERISM; STREPTOCOCCUS PNEUMONIAE;

EID: 0030004560     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.2.365     Document Type: Article

References (9)

1. Cherubin, C. E., Eng, R. H. K., Smith, S. M. & Tan, E. N. (1992). A comparison of antimicrobial activity of ofloxacin, L-ofloxacin and other oral agents for respiratory pathogens. Diagnostic Microbiology and Infectious Disease 15, 141-4.
2. Cooper, B. & Lowler, M. (1989). Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia. American Journal of Medicine 87, 475.
3. Fu, K. P., Lafredo, S. C., Foleno, B., Isaacson, D. M., Barrett, J. F., Tobia, A. J. et al. (1992). In vitro and in vivo antibacterial activities of levofloxacin (I-ofloxacin), an optically active ofloxacin. Antimicrobial Agents and Chemotherapy 36, 860-6.
4. National Committee for Clinical Laboratory Standards (1993a) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. - Third Edition; Approved Standard M 7-A3. NCCLS, Villanova, PA.
5. National Committee for Clinical Laboratory Standards (1993b). Performance Standards for Antimicrobial Disk Susceptibility Tests. - Fifth Edition; Approved Standard M2-A5: NCCLS, Villanova, PA.
6. Perez-Trallero, E., Garcia-Arenzana, J. M., Jimenex, J. A. & Peris, A. (1990). Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin European Journal of Clinical Microbiology and Infectious Diseases 9, 905-6.
7. Pfaller, M. A., Barry, A. L. & Fuchs, P. C. (1993). Levofloxacin disk potency and tentative interpretive criteria for susceptibility tests. Journal of Clinical Microbiology 31, 1924-6.
8. Righter, J. (1990). Pneumococcal meningitis during intravenous ciprofloxacin therapy. American Journal of Medicine 88, 548.
9. Sutton, L. D. & Jones, R. N. (1995). Suggested modifications of disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates. Journal of Clinical Microbiology 33, 146-8.